Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

  1. Motzer, R.J.
  2. Russo, P.
  3. Grünwald, V.
  4. Tomita, Y.
  5. Zurawski, B.
  6. Parikh, O.
  7. Buti, S.
  8. Barthélémy, P.
  9. Goh, J.C.
  10. Ye, D.
  11. Lingua, A.
  12. Lattouf, J.-B.
  13. Albigès, L.
  14. George, S.
  15. Shuch, B.
  16. Sosman, J.
  17. Staehler, M.
  18. Vázquez Estévez, S.
  19. Simsek, B.
  20. Spiridigliozzi, J.
  21. Chudnovsky, A.
  22. Bex, A.
Journal:
Targeted Oncology

ISSN: 1776-260X 1776-2596

Year of publication: 2023

Volume: 18

Issue: 5

Pages: 639-641

Type: Article

DOI: 10.1007/S11523-023-00987-1 GOOGLE SCHOLAR lock_openOpen access editor